Clinical utility of somatostatin receptor scintigraphic imaging (octreoscan) in esthesioneuroblastoma: A case study and survey of somatostatin receptor subtype expression

Head and Neck

Volumn 28, Issue 4, 2006, Pages 305-312

  Rostomily, Robert C ^a   Elias, Maria ^a   Deng, Mei ^a   Elias, Paul ^a   Born, Donald E ^a   Muballe, David ^a   Silbergeld, Daniel L ^a   Futran, Neal ^a   Weymuller, Ernest A ^a   Mankoff, David A ^a   Eary, Janet ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Esthesioneuroblastoma; Octreoscan; Somatostatin receptor; Surgery; Therapy

Indexed keywords

OCTREOTIDE; PENTETREOTIDE; PENTETREOTIDE IN 111; RECEPTOR SUBTYPE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR;

ADULT; ARTICLE; CASE REPORT; DIAGNOSTIC IMAGING; DRUG UPTAKE; ESTHESIONEUROBLASTOMA; HEALTH SURVEY; HUMAN; IMMUNOHISTOCHEMISTRY; LIGAND BINDING; MALE; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR AFFINITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SKULL BASE TUMOR; SKULL SURGERY; TUMOR GROWTH; TUMOR RECURRENCE; UTILIZATION REVIEW;

ESTHESIONEUROBLASTOMA, OLFACTORY; HUMANS; INDIUM RADIOISOTOPES; MALE; MIDDLE AGED; NASAL CAVITY; NOSE NEOPLASMS; OCTREOTIDE; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TUMOR MARKERS, BIOLOGICAL;

EID: 33645692124     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.20356     Document Type: Article

References (22)

1. Virgolini I, Traub T, Novotny C, et al. Experience with indium-111 and yttrium-90-labeled somatostatin analogs. Curr Pharm Des 2002;8:1781-1807.
2. Breeman WA, de Jong M, Kwekkeboom DJ, et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 2001;28:1421-1429.
3. Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med 2000;41:1704-1713.
4. Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 2002;32:148-155.
5. Garcia Vicente A, Garcia Del Castillo E, Soriano Castrejon A, Alonso Farto J. [Olfactory esthesioneuroblastoma: scintigraphic expression of somatostatin receptors]. Rev Esp Med Nucl 1999;18:367-370.
6. Ramsay HA, Kairemo KJ, Jekunen AP. Somatostatin receptor imaging of olfactory neuroblastoma. J Laryngol Otol 1996;110:1161-1163.
7. Pasquali D, Vassallo P, Esposito D, Bonavolonta G, Bellastella A, Sinisi AA. Somatostatin receptor gene expression and inhibitory effects of octreotide on primary cultures of orbital fibroblasts from Graves' ophthalmopathy. J Mol Endocrinol 2000;25:63-71.
8. Kulaksiz H, Eissele R, Rossler D, et al. Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut 2002;50:52-60.
9. Nilsson O, Kolby L, Wangberg B, et al. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours. Br J Cancer 1998;77:632-637.
10. Papotti M, Croce S, Bello M, et al. Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumours. Correlation with preoperative octreotide scintigraphy. Virchows Arch 2001;439:787-797.
11. Kropp J, Hofmann M, Bihl H. Comparison of MIBG and pentetreotide scintigraphy in children with neuroblastoma. Is the expression of somatostatin receptors a prognostic factor? Anticancer Res 1997;17:1583-1588.
12. Meewes C, Bohuslavizki KH, Krisch B, Held-Feindt J, Henze E, Clausen M. Molecular biologic and scintigraphic analyses of somatostatin receptor-negative meningiomas. J Nucl Med 2001;42:1338-1345.
13. Rieger A, Rainov NG, Elfrich C, et al. Somatostatin receptor scintigraphy in patients with pituitary adenoma. Neurosurg Rev 1997;20:7-12.
14. Muller HL, Fruhwald MC, Scheubeck M, et al. A possible role for somatostatin receptor scintigraphy in the diagnosis and follow-up of children with medulloblastoma. J Neurooncol 1998;38:27-40.
15. Luyken C, Hildebrandt G, Scheidhauer K, Krisch B, Schicha H, Klug N. 111Indium (DTPA-octreotide) scintigraphy in patients with cerebral gliomas. Acta Neurochir (Wien) 1994;127:60-64.
16. Cervera P, Videau C, Viollet C, et al. Comparison of somatostatin receptor expression in human gliomas and medulloblastomas. J Neuroendocrinol 2002;14:458-471.
17. Virgolini I, Traub T, Novotny C, et al. Experience with indium-111 and yttrium-90-labeled somatostatin analogs. Curr Pharm Des 2002;8:1781-1807.
18. Reubi JC, Lang W, Maurer R, Koper JW, Lamberts SW. Distribution and biochemical characterization of somatostatin receptors in tumors of the human central nervous system. Cancer Res 1987;47:5758-5764.
19. Lee JD, Kim DI, Lee JT, Chang JW, Park CY. Indium-111-pentetreotide imaging in intra-axial brain tumors: comparison with thallium-201 SPECT and MRI. J Nucl Med 1995;36:537-541.
20. Dulguerov P, Allal AS, Calcaterra TC. Esthesioneuroblas toma: a meta-analysis and review. Lancet Oncol 2001;2: 683-690.
21. McElroy EA Jr, Buckner JC, Lewis JE. Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience. Neurosurgery 1998;42:1023-1027; discussion 1027-1028.
22. Chamberlain MC. Treatment of intracranial metastatic esthesioneuroblastoma. J Clin Oncol 2002;20:357-358.